Review
Open access
Sep 2026
Contemporary Management of Thalassemia: A Perspective on Current Standards and the Emergence of FDA‐Approved Oral Therapy
Mitapivat represents a significant advance in thalassemia management by targeting erythrocyte metabolism and providing the first FDA‐approved oral treatment for anemia in adults with α or β thalassemia.
Fnu Zainab, Abdul Haseeb Hasan, Muhammad Hafi Abid et al.
· Health Science Reports · 0 citations